Master of Molecular Medicine Module IV Functional Genomics

RNAseq & alternative splicing

Uwe Ohler Max Delbrueck Center uwe.ohler@mdc-berlin.de

The regulatory genome: transcription



Variation & evolution (whole-genome sequencing) Chromatin structure (histone modifications; "epigenetic code") Promoter & enhancers (mapping target sites of regulatory factors) Transcript variants + expression (RNA sequencing)

Post-transcriptional regulation



The impact of deep sequencing

- In the past years, new sequencing technologies have made the anticipated quantum leap
 - Illumina HiSeq: typically ~100-200 mio reads of ~100 bp
 - Unbiased exploration of genomes (DNA) & transcriptomes (RNA)
 - We can now study the 98% of the genome that is non-coding (and not only the 2% that codes for proteins)



Platforms

- Most popular approach: amplification & sequencing by synthesis
 - "short" reads, 100+ bp
 - Reversible dyes (Illumina, since 2008)
 - Microfluidics, pH based (Ion Torrent, since 2010)

• Single molecule sequencing

- Longer reads, 1000+bp; each molecule is sequenced multiple times
- Example: PacBio



ENEYCLOPEDIA OF DNA ELEMENTS

| | | | | 50000 l | | 100 | cco | | 150000 | 1 | 2 | 00000 1 | Human May 2 | 004 chr1 25000 | 6:1-500,000 0 | (500,000 bp) 304 | 1 0000 | | 350000 | 1 | 400 | 1 0000 | | 4500 | 1 00 | |
|-----------------------------|--------------------------------------|-------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------|---------|-------------|--------|---------|-----------|----------|-------------|-------------------|------------------|---------------------|------------------|-----------|--------|----------|---------------|-----------|-----------|-----------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GENCODE Known Genes | 284812.2 284723.1 | H | POLR 01 | 3K +++ 6ort33 ++ | MPG H C160ft3 | *** | | 28 | HBZ | HBA2 | LUO7L 4+- | ++++ | C16019 # | | ARHODI | ig H | | | MPE | MEM8 | DECR2 I | FABITE | 1P3 (**** | | | |
| | | | | RHODFIM | HH1 | | | | | HBAT | 11 | | | 1 | AG511 | | | | | | | | | | | |
| GENCODE Putative Genes | Z84812.1 | | | | | | Z69895. | 21 | | | | | | ACCO | 4754.3 HI | | | | | Z97834.5 | areas a | | | | | |
| Pseudogenes Con | sensus Pseudogenes Known+Pred RNA | • | H | | | 121 | | | | H | E. | | 1.11 | | - E | IEE | | | I | 1 | | | | 1 | | 4 |
| RNA Secondary Structure | EvoFold RNAz | | 11 | 1.1 | | W1* | 1111 | | ı | 1.1 | 1111 | 1 1 | 1 I III I | 11.8.1 | 1.00 | | 1 ¹ 1 | н. 1 | 111 | | 1 1 | u | Ψ | ngr - | 1 111 | 1.11.1 |
| CpG Islands | OpG Islands | | L | 1 | 1 11 | 7. 1 | 2 | 1 | 1 | . 1 | 111 | | 111 | | | | | 1 | | I | 1.1 | II I | | | | 1 . |
| cDNA Paired-End Tags | MCF7 HCT116 | | | | | 1 | | - | | - | | | | | | нн | | | 1 | 1 H | | | | - | | |
| RNA Transcription | GM06990 | - | | | | | | | | | 110 | 1 1 | 1 11 | 1111 | | 1111 | | | 111 | 1 111 | | | | | 11112 | 1.1.1.1 |
| | HL-60 | | april 1 | | 100 | | | | | 110 | | B 11 | 1 111 | 1 | - Statistics | 11111 | | | 1.11 | 1 1 1 1 | 1 | 1.11 | | 12.13 | | |
| | Placenta NB4 | | | 1 | III I | 111 11 | | 1 | 1 | 11 | 111 | 3 | 1 | 1 | 138 | i i | | | | i initi | 1 1 | | | 1 | | |
| P.C. Andreho P.C. Press | | | | | | | | | | | | | | | | | | | | | | | | | 1.18 | |
| 5 Cap Analysis of Gene Expr | CAGE - | | 1 | 11 | 100 | | | n'nk | | 11.1 | | 1.1 | 11 | | 101 | | | | 60 I I | | 1.1 | | 1 | | 1.1.1 | |
| PoHI / TAF1 | Pol2 HeLz Pol2 IMR90 | - | 11111 | 1 | | 1 1 | | | | | | 1 18 | | | | 1 | | 1 | | 1 | 811 F | 1 | 1 | | | |
| | TAF1 HeLs TAF1 IMB90 | | | 1 | | | | | | | | 1.18 | | | | | | 1 | | | | 1 | 1 | | | |
| | Pul2 GM06990 | | i natio | 1100 | | 11 | | | n i in | | | 1.10 | | 10 i i | | | | ni ini di | | | B illi | 1 | 1.11 | i din | | |
| Promoter Activity | HMCB Hels | | | | 1 | | 1 | | | | | | | | | | | | | | | | | | | |
| | HepG2 JEG3 | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Snu182 | | | 1 | | | 1 | | | | II | | | | | | | | 11 | | 1 | | | | | COMPANYING |
| Histone Modification | H3K4me1 GM06990 H3K4me2 GM06990 | | | a de la comercia de l | | | | | 11 | 11 | | 1 6 | 1.8 | | | | | | 11 | | | | | | | |
| | H3K4me3 GM06990 H3ac GM06990 | | | | | | | | | - 1-1 B | | | . 140 | | | | | | | | | - | Π. | 1 | | |
| | H4ac GM06990 H4Kac4 GM06990 | | 10.00 | 1081 | | 0 | 1.01 | DI 10. | 611 | | 5366 | 1 80 | REPUBLI | UR D I | | | 11 9 | a de sas | 111 | la deni | ita da si | 1 | (0. | (min a d | and the second | C COMPANY. |
| | H3K4me1 HeLs H3K4me2 HeLa | | | | i I | | 11 | | | - Tř | i | 1 🗐 | 1.1 | | | | | 1 | | | 1 | 1 | | | | |
| | H3K4me3 HeLa H3ac HeLa | | | 1 | 11 | | | | | | | 1 11 | | | | | | | | | | ľ. | | | | |
| | H4ac HeLa H4Kao4 HeLa | | | | | 1 | 1.1 | 1.11 | Ц | | . 1 | 1.1 | 11111 | н. : | | | | 1.11 | 111 | | П. | | | 10.0 | 11 | 1 |
| DNasel Sensitivity | CD4 | 181.1 | 1.1.8 | 1.1 | LU | 11 1. | 1 1 | 1 | 11 | . 8.11 | 1.1 | | 11 | | F I | 1. 1. | | 181 | 1 10 | 1.1.1 | a 1.1 | 1. | 1 | | ι. | |
| | HepG2 CaCo2 | 1.000 | 1. 10 | 1 | 1 de | 1 | 10 1000 | 1 | | 1.000 | 1 | unita | 11 | | month | | | | E | 11 | in a rel | P | n Man | 101215 | 1000200 | tin marked |
| | Adult Eryth Fetal Eryth | | 1 | | | 100 | 1 | 1 | 1 | | 11 | | 11 | | | 1 1 | | 1 | 1 | | | 1 | | | | |
| | SKnSH | | | | | | | | | | Ι. | | 11 | | | | | | | | | 1 | | | | |
| Nuclearance and Basing | GM06990 | | | | | | | | | | | 1. 1. | | 1000 | - Constanting | Constant of | and simple a | | | 1 | | | 1 | | a la contra lana | A IN ADDRESS OF A DESCRIPTION OF A DESCRIPANTE A DESCRIPANTE A DESCRIPANTE A DESCRIPTION OF A DESCRIPTION OF |
| Hydroxyl Radical Cleavage I | rtensity ORChiD | 0.00 | 10 THE | 1 | 前行事 | and a | | il de la co | 11 | 10 11 | IT I | Engloss. | | III . | THE R | NI II | al of A | | 1 | 南南部 | and the | d op a co | | | 1 11 | ULT TH |
| Regulatory Factors | BAF155 HeLE BAF170 HeLE | 11 | | | | | | 11 | 11 | | | 1 (1) | | in a r | 10011000 | | | | | | | | 11 | | | |
| | c-Fos HeLa | I.I. | | | | | | | | | | | | | 11188 | | | | | | | | 1 | | | |
| | E2F1 HeLs | | | | 111 | 1 | | | | 1 1 | | | | | | | 1 | | 1 | 1 | | 1 | i | T. | | |
| | STAT1 Hels | | 1 0000 | | | | | | | | | | | 1000 | 1 | | | 1 | | | | | 100 | 14 | | CARDEN. |

ENCODE 2012

Computational challenges

"Deep sequencing" is a catch-phrase for 100s of different biochemical assays,

with some common and some application specific tasks

- 1. Mapping reads to the genome or transcriptome
 - Spliced or contiguous
 - Example read aligners: Bowtie, BWA, STAR (Cufflinks; Scripture, etc)
- 2. Quantifying read density
 - Identification of sequence variation (exome seq)
 - Gene expression changes
 - Protein/DNA (or RNA) interactions

Protein coding genes and splice sites

- Most eukaryotic protein-coding genes have a split gene structure of exons and introns
- Conserved sequence motifs mark beginning and end of exons



Steps in RNA splicing



Introduction

Classical (long read) transcript structure assembly

Given an incomplete and complementary transcript sequence (cDNA/mRNA), find the complete genomic sequence (primary transcript structure) and determine the gaps (introns)

 Align sequences with gaps and determine
 'best' match

- Gaps start/end with 5'ss and 3'ss signals



Genomics of splicing

Short-read spliced alignment

- From expression quantification of whole genes, to exons, and isoforms
 - Alignment to known isoforms
 - Simultaneous reconstruction and quantification



Signals: RNA binding sites recognized by the spliceosome



Splicing regulatory elements

The reality is of course more complicated

 In higher eukaryotic genomes (beyond yeast), splice sites alone often do not contain sufficient information for accurate splicing, compensated for by splicing regulatory elements in both exons and introns



Introduction

Signals and trans-acting factors



| Signal/Species | 5 ' ss | BP | 3'ss | |
|----------------|---------------|----|------|----|
| S.cerevisiae | 11 | 12 | 7 | 30 |
| C.elegans | 8 | 5 | 11 | 24 |
| D.melanogaster | 9 | 5 | 10 | 24 |
| H.sapiens | 8 | 5 | 8 | 21 |
| | | | | |

Weaker splice sites, yet more signals enhancing (ESE) or silencing (ESS) exons in higher eukaryotes

Splicing regulatory elements

Illustrative example: the NMDA-type glutamate receptor



RNA-binding proteins attracted to multiple sequence elements: SR proteins, hnRNPs many (but not all) are conserved

Introduction

Grabowsky (2005)

Splicing regulation of PTB exon skipping by its own protein



Autoregulatory functional loop: steady state level of E11 skipping low (<1%), skipping of E11 causes frame-shift and creation of premature termination codon (PTC) in E12 (>55 bp of authentic stop codon), substituting the substrate to NMD pathway

Tissue-specific exon switch using *trans*-regulatory factors



Clusters of alternative exons in Drosophila's Dscam gene



A repertoire of alternative splicing patterns



Alternative splicing

Functional roles and consequences of alternative splicing

| RNA splicing and Plasticity of alternative splicing | | | | | | | | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|--|
| Snliceosome | RNA | Protein functional | Splicing errors in | | | | | | | | |
| function | processing | diversity | human disease | | | | | | | | |
| Precise recognition of splice sites among many pseudo-sites Removal of introns Production of correct message | Coupling interaction of RNA splicing with gene expression: Transcription Capping and Polyadenylation mRNA export Surveillance and mRNA degradation | Cell and tissue-specific mRNA isoforms Developmental stage regulated isoforms Inducible control and expression of isoforms | Inherited mutations and effects of genetic background affecting Authentic splice sites Alternative splice sites Basal splicing machinery Trans-acting regulators of AS Tumorigenic phenotypes and progression | | | | | | | | |

Alternative splicing

Deep sequencing surveys

- Frequency and relative abundance of alternative splicing isoforms in human genes [Wang et al, 2008]
 - 10 tissues, 5 breast cancer cell lines, > 400 mio reads
 - 94% of human genes are multi-exon;

~86% have >=2 isoforms at reasonable levels



Types and abundances of mammalian AS patterns



Tissue-specific vs individual-specific variation

- Tissue-specific variation exceeds individualspecific variation
 - 10-30% of AS events vary between individuals;
 47-74% differ between tissues



Quantification of regulatory interactions



RNA binding proteins: From RIP-chip to CLIP-seq

- RIP: RNA immunoprecipitation (transcripts)
- CLIP: RNA cross-linking and IP (sites)



RBP **RNA** k = iUV crosslink site Partial RNAse digestion, immunoprecipitation, 3' linker ligation, RNA-labeling & SDS-PAGE 3' linker Digestion with proteinase K, RNA purification & 5' linker ligation Reverse transcription **cDNA** Frequency PCR amplification High-throughput sequencing

Keene, Darnell labs

Pum1 RIP-chip

- Pum1: Member of a very widely conserved RBP family (yeast to human)
 - Enhances decay, represses translation



Morris et al, MCB 20008

Changing targets across evolution

• Conserved protein, conserved motif, but different targets with different functions

| A . | | Genes with human orthologues | Pum1 target genes | Percent conserved target genes | P-value of enrichment (sampling) | P-value of enrichment (Fisher's exact) | |
|------------|-------------------------|------------------------------------|----------------------|--------------------------------------|----------------------------------------|-------------------------------------------------|--|
| | Puf3 target genes | 89 | 7 | 7.87% | 0.83 | 0.79 | |
| | Pumilio target genes | 502 | 73 | 14.54% | 0.018 | 0.036 | |



PAR-CLIP



Identifies the locations of interaction between RNA-binding proteins (RBPs) and their mRNA targets in a high-throughput manner

- Think of it as a ChIP-Seq on an RNA level
- Presence of T->C conversions indicates crosslinked sites

Hafner et al, Cell 2010

PARalyzer: RBP site identification



Corcoran et al, Genome Biol 2011

Genetic diseases caused by loss or mutation of miRNAs or RBPs



Example I: Deep sequencing delineates target sites and sequence preferences of FMR1



Ascano et al, Nature 2012

I304N mutation: Lower Read Depth of ACUK Clusters

-CLIP FMR1 iso7 wt vs. I304N



FMR1 binding sites on selected mRNAs



Embryonic stem cell differentiation and alternative splicing

- Muscle blind-like proteins (MBNL): conserved and direct regulators of exon skipping/inclusion
- Overexpression in ES cells promotes AS patterns of differentiated cells
- One of the targets: FOXP1
 - Switched exon spans TF binding domain, changes affinity in ES cells
 - ES cell splicing directs it to express pluripotency factors



Linking splicing changes and RBP binding



Han et al, Nature 2013

Take home points: next-gen sequencing is...

- Unbiased
 - Not limited to classical coding genes
 - Not limited to gene proximal regions
- High resolution
 - Expression on the level of isoforms
 - Interactions up to single nucleotide precision
- Cheap
 - Whole genome now < \$1,000</p>